AIDOT (CEO Jung Jae-hoon) announced on the 7th that it introduced “Cerviray (Cerviray AI)” at the International Gynecologic Cancer Society (IGCS: International Gynecologic Cancer Society) annual international conference (Annual Global Meeting 2023), held at COEX in Seoul.

IGCS is the largest gynecologic oncology academic organization, with more than 3,000 gynecologic oncology specialists worldwide participating as members. On that day, Professor Kim Sung-min of the Gynecologic Oncology Center at Ilsan CHA Hospital presented on the excellence of Cerviray under the topic “Efficacy and safety of assistive AI-based software for cervical cancer diagnosis (Pivotal clinical study to evaluate the efficacy and safety of assistive AI-based software for cervical cancer diagnosis)”, drawing the attention of many specialists.

Professor Kim Sung-min of Ilsan CHA Hospital said, “It is highly meaningful in that it has opened a way for many women in countries and regions where periodic screening was not possible to receive cervical cancer screening through Cerviray (Cerviray AI) without barriers related to medical infrastructure.” He also said, “Cerviray (Cerviray AI), which has high accuracy and clinical effectiveness in identifying the location of lesions and making diagnoses for both experienced and inexperienced colposcopy examiners for cervical cancer, can be used as an assistive tool, and it can also help inexperienced colposcopy examiners confirm the location for performing a biopsy to diagnose high-grade lesions.”

Meanwhile, in addition to Cerviray, AIDOT is stepping up its push into global markets by showcasing various medical AI solutions such as an upper endoscopy AI solution (GIGA dot AI), a colonoscopy AI solution (COLON dot AI), and a microbiome-based AI solution for alcoholic liver disease (BIO dot AI).

Korea Economic TV / 2023.11.08 / Senior Reporter Yang Jae-joon